1,300th Implant of the SynCardia Total Artificial Heart Was Performed in April 2014 When All Other Treatments Fail, the SynCardia Total Artificial Heart Can Save the Sickest of the Sick. The Freedom Portable Driver Allows a Majority of SynCardia Patients to be Discharged from the Hospital to Live at Home & Get In Better Shape for Their Heart Transplant.
TUCSON, Ariz., May 20, 2014 /PRNewswire/ -- SynCardia Systems, Inc. announced today that a United States patient with end-stage biventricular heart failure received the 1,300th implant of the SynCardia temporary Total Artificial Heart as a bridge to transplant in April 2014.
"The SynCardia Heart saves patients dying of end-stage biventricular (both sides) heart failure and the Freedom® portable driver provides patients without human hearts a life worth living outside the hospital," says Michael P. Garippa, SynCardia CEO and President. "Discharge on the 13.5-pound Freedom portable driver improves the patient's quality of life with nearly unlimited mobility while eliminating most in-hospital costs for this portion of their care."
According to the New England Journal of Medicine (N Engl J Med 2004;351:859-67), Total Artificial Heart patients have the highest bridge to transplant rate of any approved device, 79%. During the last 24 months there have been over 300 implants of the SynCardia Heart.
Similar to a heart transplant, the SynCardia Total Artificial Heart replaces the two failing ventricles and four heart valves. It is the only device that eliminates the source and symptoms of end-stage heart failure.
Over 175 patients have been supported by the Freedom® portable driver totalling over 100 years of support.
Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage biventricular heart failure in which both ventricles no longer can pump enough blood for the patient to survive.
The SynCardia Heart has been used to address multiple heart failure etiologies that may lead to end-stage biventricular failure, including cardiac tumor, ventricular septal defect, LVAD (left ventricular assist device) failure, heart transplant failure, arrhythmias and heart attack.
CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end stage heart failure affecting both sides of the heart (biventricular failure).
The SynCardia Heart has provided nearly 400 patient years of life from more than 1,300 implants, including more than 400 implants since January 2011. The youngest patient to receive a SynCardia Heart was 9 years old; the oldest was 76 years old.
Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at 97 SynCardia Certified Centers worldwide with 39 others in the process of certification.
The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
SOURCE SynCardia Systems, Inc.